title: Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.
abstract: Approximately 170 million people harbor chronic infection with hepatitis C virus (HCV) worldwide, with 3-4 million in the United States. As recently as 2013, the few treatment options available were poorly tolerated and only moderately effective. That changed when the first interferon-free direct-acting antiviral (DAA) regimen was US Food and Drug Administration-approved in December 2013. There are now 10 approved DAAs, with several more deep in the pipeline to approval. There are now interferon-free regimens available for every HCV genotype, and the application of DAA combination regimens has lifted response rates for historically difficult-to-treat patient groups to levels on par with more conventional treatment groups, including persons with HIV/HCV coinfection. This review will summarize the data behind currently recommended DAA regimens, review the data for treatment of HIV/HCV-coinfected patients, and discuss important drug-drug interactions between HCV DAAs and HIV antiretrovirals.
authors.affiliation: Massachusetts General Hospital, Division of Infectious Diseases, Boston, MA, USA.
authors.forename: Justin
authors.initials: J
authors.lastname: Chan
authors.affiliation: Massachusetts General Hospital, Division of Gastroenterology, Boston, MA, USA.
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Chung
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy*; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: HIV; HIV/HCV coinfection; direct-acting antivirals; drug interactions; hepatitis C